Compare Hut 8 Corp (HUT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Sana Biotechnology Inc — how do they compare? Hut 8 Corp trades at $110.17 (market cap $11.36B), while Sana Biotechnology Inc trades at $3.2 (market cap $873.84M). The key difference: Hut 8 Corp is far larger — about 13× Sana Biotechnology Inc's market cap, and Hut 8 Corp is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| HUT | SANA | |
|---|---|---|
Market Cap | $11.36B | $873.84M |
Sector | Technology | Health |
52-Week High | $133.02 | $5.92 |
52-Week Low | $19.45 | $2.68 |
Enterprise Value | $11.63B | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $100.93, up 10.37% in the past 24 hours, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, though it beat EPS estimates in two of the last three quarters. Recent news highlights its pivot to AI infrastructure, including a $4.25 billion bond issuance for data center projects (PRNewsWire, 2026-06-09).
Analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent losses pose risks. The stock's outlook hinges on successful execution of its digital infrastructure strategy, though cash flow challenges and competitive pressures remain key concerns for investors.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
